Related Content
- Pfizer forms licensing agreement with Seattle Genetics
- Walgreens puts its money where its mouth is with World AIDS Day campaign
- Walgreens allies with HHS to launch free flu shot outreach to disadvantaged
- Walgreens launches high-impact push in support of World AIDS Day campaign
- Moving PSE to Rx-only in Mo. lacks fiscal sense
SCHAUMBURG, Ill. — Generic drug maker Sagent Pharmaceuticals has launched a new drug for neuromuscular disorders, the company said.
Sagent announced the launch of vecuronium bromide, an injectable drug used to treat myasthenia gravis and Eaton-Lambert syndrome. The disorders cause muscle weakness and fatigue.
The market for vecuronium bromide is about $10 million in the United States, according to IMS Health.
